Sarepta Therapeutics/$SRPT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
- Ticker
- $SRPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 835
- Headquarters
- Cambridge, United States
- Website
- www.sarepta.com
SRPT Metrics
BasicAdvanced
$1.9B
-
-$1.09
-
-
Price and volume
Market cap
$1.9B
52-week high
$24.68
52-week low
$14.68
Average daily volume
2.5M
Financial strength
Current ratio
3.463
Quick ratio
1.901
Long term debt to equity
0.585
Total debt to equity
0.689
Interest coverage (TTM)
-0.22%
Profitability
EBITDA (TTM)
23.756
Gross margin (TTM)
-21.01%
Net profit margin (TTM)
-5.86%
Operating margin (TTM)
-0.43%
Effective tax rate (TTM)
-24.56%
Revenue per employee (TTM)
$2,340,000
Management effectiveness
Return on assets (TTM)
-0.16%
Return on equity (TTM)
-8.05%
Valuation
Price to revenue (TTM)
0.959
Price to book
1.25
Price to tangible book (TTM)
1.25
Price to free cash flow (TTM)
10.948
Free cash flow yield (TTM)
9.13%
Free cash flow per share (TTM)
1.628
Growth
Revenue change (TTM)
-18.95%
Earnings per share change (TTM)
-24.96%
3-year revenue growth (CAGR)
20.98%
10-year revenue growth (CAGR)
108.62%
3-year earnings per share growth (CAGR)
-48.16%
10-year earnings per share growth (CAGR)
-14.58%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
Analyst projections of the future price of Sarepta Therapeutics stock.
Bulls say / Bears say
A two-year analysis of 25 ambulatory patients aged 8–12 found better motor-function measures than matched external controls, extending the efficacy case into older patients. The comparison was not randomised, so the findings still need confirmation. (BioSpace)
The established PMO franchise generated $230.6 million in Q2 net product sales, while Sarepta reported $13.3 million in GAAP operating income and $945 million in cash, restricted cash and investments. This commercial base helps fund the company’s development programmes. (Sarepta Therapeutics)
Phase 1/2 multiple-ascending-dose readouts for FSHD and DM1 remained on track for the second half of 2026, and dosing had begun in Sarepta’s first-in-human Huntington’s study. These programmes offer potential growth beyond Duchenne, although they are still early-stage. (Sarepta Therapeutics)
ELEVIDYS net product sales fell to $98.1 million in Q2 from $281.9 million a year earlier after its label was restricted to ambulatory patients. Sarepta also narrowed its 2026 net product revenue guidance to $1.2–$1.3 billion, signalling continued commercial pressure. (Sarepta Therapeutics)
A second non-ambulatory patient reportedly died from acute liver failure after receiving ELEVIDYS, prompting a pause in commercial dosing for non-ambulatory patients and in the ENvision confirmatory trial. The renewed safety concern could hinder any effort to restore broader use. (Center for Genetics and Society)
Amondys 45 and Vyondys 53 failed to significantly improve motor function versus placebo in their ESSENCE confirmatory trial. Although the FDA accepted applications to convert them to traditional approval, the trial result leaves a key efficacy question unresolved ahead of the 2027 decisions. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
Upcoming events
No upcoming events
SRPT News
AllArticlesVideos
Sarepta Therapeutics Q3 Earnings Call Highlights
MarketBeat3 days ago
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Business Wire2 weeks ago
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Business Wire4 weeks ago
Funds containing SRPT
AllUSDEURGBP
Fund name | Fund size | $SRPT weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.18% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.18% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.18% |
iShares Ageing Population$AGED | $953M | 0.16% |
iShares Ageing Population£AGES | $953M | 0.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.